Esbriet

April 6, 2021April 6, 2021

Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice

Esbriet, News

Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) ... Read more

February 11, 2021February 11, 2021

FDA Grants Priority Review to Esbriet for Unclassifiable Interstitial Lung Disease

Esbriet

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to an application for Esbriet (pirfenidone) as a treatment for unclassifiable interstitial lung disease (UILD). The supplemental ... Read more

June 3, 2020June 3, 2020

Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

Esbriet, News

Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37% lower than patients not treated with such therapies, a large registry-based study reports. ... Read more

May 27, 2020May 27, 2020

Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF

Esbriet, News

A real-world, multi-center study in Poland confirms the effectiveness and safety of two-year treatment with Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF). The study “A multicentre retrospective observational study on Polish ... Read more

January 8, 2020January 8, 2021

Esbriet at Low Dose Effectively Treats IPF, Real-world Study Finds

Esbriet, News

Low daily doses of Esbriet (pirfenidone), less than 1200 mg per day, are equally effective at slowing lung function decline in people with idiopathic pulmonary fibrosis (IPF) as higher daily ... Read more

November 5, 2019November 5, 2019

PROOF Real-world Data Continues to Show Esbriet’s Ability to Preserve Lung Function in IPF

Esbriet, News

Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with idiopathic pulmonary fibrosis (IPF), real-world data from the PROOF registry show. The results were ... Read more

September 10, 2019September 11, 2019

Real-world Esbriet Results Are Comparable to Those of Clinical Trials, Study Says

Esbriet, News

Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in clinical trials, a new study shows. “Pirfenidone in real life: A ... Read more

August 16, 2019August 16, 2019

Taking Esbriet for IPF Does Not Increase Risk of Heart Problems, Analysis Says

Esbriet, News

Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of the ... Read more

June 19, 2019June 21, 2019

Esbriet Helps Halt Breathlessness Symptoms in Severe IPF, Analysis of Multiple Trials Shows

Esbriet, News

Treatment with Esbriet (pirfenidone) slows the worsening of breathlessness in patients with more severe idiopathic pulmonary fibrosis (IPF), a post-hoc analysis of the ASCEND and CAPACITY trials shows. The study, ... Read more

April 8, 2019

Secondary Insurance Coverage Boosts Adherence to Treatment with Ofev, Esbriet, Study Finds

Esbriet, News

Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence to treatment is higher among those who have secondary insurance coverage, especially ... Read more